Does Cosentyx Require Vaccine Booster Shots?
No, Cosentyx (secukinumab) does not require associated vaccine booster shots. It is an IL-17 inhibitor used for psoriasis, psoriatic arthritis, ankylosing spondylitis, and other inflammatory conditions. Live vaccines are contraindicated during treatment due to immunosuppression risks, but inactivated or recombinant vaccines (like most COVID-19 boosters) can be given with monitoring.[1]
Why Vaccination Timing Matters with Cosentyx
Patients on Cosentyx face higher infection risks, including from respiratory viruses. Guidelines recommend completing vaccinations before starting therapy:
- Live vaccines (e.g., MMR, varicella, oral polio): Avoid entirely while on Cosentyx and for several weeks after stopping.
- Non-live vaccines (e.g., Tdap, influenza, shingles, pneumococcal, COVID-19 boosters): Safe to administer, though antibody responses may be reduced. Boosters follow standard schedules unless infection or severe immunosuppression alters them.[2][3]
COVID-19 Boosters Specifically for Cosentyx Users
No special booster protocol exists for Cosentyx. CDC and EMA advise immunocompromised patients—including those on biologics like secukinumab—to get extra COVID-19 doses or boosters as recommended for their group (e.g., additional mRNA doses). Real-world data shows adequate but sometimes blunted responses; testing antibody levels isn't routine.[4]
Common Infection Risks and Prevention Strategies
Cosentyx increases upper respiratory and fungal infection rates (e.g., candidiasis). Prevention focuses on:
- Annual flu shots.
- Pneumococcal vaccines (PCV20 or PPSV23 series).
- Shingles vaccine (Shingrix, two doses).
Patients report breakthrough infections; boosters help mitigate this without drug-specific adjustments.[5]
Switching from Cosentyx or Other Biologics
If pausing Cosentyx for vaccination, wait 4-6 months for drug clearance before live vaccines. No booster "need" ties directly to the drug—standard schedules apply. Consult rheumatologists for personalized plans, especially with comorbidities.[1][2]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: ACR Guidelines on Vaccinations in Rheumatic Diseases
[3]: EMA Cosentyx Summary of Product Characteristics
[4]: CDC Immunocompromised Vaccination Guidance
[5]: Clinical Trials Data on Secukinumab Infections (Novartis)